Drug Type Small molecule drug |
Synonyms C3001a |
Target |
Action stimulants, agonists |
Mechanism TREK1 stimulators(KCNK potassium channel-2 stimulators), TREK2 agonists(potassium two pore domain channel subfamily K member 10 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H20N2O3S |
InChIKeyOUAZWUKQRHZQNC-CABCVRRESA-N |
CAS Registry2415154-29-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurogenic Inflammation | Preclinical | China | 09 Apr 2020 | |
Pain | Preclinical | China | 09 Apr 2020 |